tiprankstipranks
Astellas Pharma Inc (JP:4503)
:4503
Japanese Market
4503
Astellas Pharma
RESEARCH TOOLSreports
Want to see JP:4503 full AI Analyst Report?

Astellas Pharma (4503) Stock Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

4503 Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
3 Buy
5 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Astellas
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4503 Stock 12 Month Forecast

Average Price Target

¥2,593.75
▲(1.58% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is ¥2,593.75 with a high forecast of ¥2,950.00 and a low forecast of ¥2,200.00. The average price target represents a 1.58% change from the last price of ¥2,553.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1336":"¥1,336","2951":"¥2,951","1739.75":"¥1,739.8","2143.5":"¥2,143.5","2547.25":"¥2,547.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2950,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥2.95K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2593.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥2.59K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥2.20K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1336,1739.75,2143.5,2547.25,2951],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2207,2264.153846153846,2321.3076923076924,2378.4615384615386,2435.6153846153848,2492.769230769231,2549.923076923077,2607.076923076923,2664.230769230769,2721.3846153846152,2778.5384615384614,2835.6923076923076,2892.846153846154,{"y":2950,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2207,2236.75,2266.5,2296.25,2326,2355.75,2385.5,2415.25,2445,2474.75,2504.5,2534.25,2564,{"y":2593.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2207,2206.4615384615386,2205.923076923077,2205.3846153846152,2204.846153846154,2204.3076923076924,2203.769230769231,2203.230769230769,2202.6923076923076,2202.153846153846,2201.6153846153848,2201.076923076923,2200.5384615384614,{"y":2200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1383.867,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1369.922,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1337.705,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1516.098,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1580.531,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1585.445,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1589.385,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1941.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2061.719,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2118.359,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2447.368,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2657.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2207,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target¥2,950Average Price Target¥2,594Lowest Price Target¥2,200
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on JP:4503
Miki Sogi
Bernstein
Bernstein
¥2,200
Hold
-13.84%
Downside
Reiterated
05/12/26
Astellas Rated Hold as Xtandi Headwinds Offset Pipeline Potential; Price Target Reiterated at ¥2,200
Citi Analyst forecast on JP:4503
Hidemaru Yamaguchi
Citi
Citi
¥2,500→¥2,400
Hold
-6.01%
Downside
Reiterated
05/01/26
Astellas Pharma (ALPMF) Gets a Hold from Citi
Goldman Sachs Analyst forecast on JP:4503
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
¥2,800→¥2,950
Buy
15.53%
Upside
Reiterated
04/28/26
Goldman Sachs Sticks to Its Buy Rating for Astellas Pharma (ALPMF)
UBS Analyst forecast on JP:4503
Unknown Analyst
UBS
Not Ranked
UBS
¥2,350→¥2,600
Hold
1.82%
Upside
Reiterated
04/16/26
Astellas Pharma (ALPMF) Receives a Hold from UBS
Jefferies Analyst forecast on JP:4503
Stephen Barker
Jefferies
Jefferies
¥2,800
Buy
9.65%
Upside
Reiterated
03/24/26
Jefferies Keeps Their Buy Rating on Astellas Pharma (ALPMF)
J.P. Morgan Analyst forecast on JP:4503
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
¥2,500
Hold
-2.10%
Downside
Reiterated
03/23/26
J.P. Morgan Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Mizuho Securities Analyst forecast on JP:4503
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
¥2,500
Hold
-2.10%
Downside
Reiterated
03/19/26
Astellas Pharma (ALPMF) Receives a Hold from Mizuho Securities
Macquarie Analyst forecast on JP:4503
Unknown Analyst
Macquarie
Not Ranked
Macquarie
¥2,500→¥2,800
Buy
9.65%
Upside
Reiterated
03/16/26
Macquarie Reaffirms Their Buy Rating on Astellas Pharma (ALPMF)
Nomura Analyst forecast on JP:4503
Unknown Analyst
Nomura
Not Ranked
Nomura
¥2,400→¥2,500
Hold
-2.10%
Downside
Downgraded
02/19/26
Nomura downgrades Astellas Pharma (ALPMF) to a Hold
SMBC Nikko Analyst forecast on JP:4503
Unknown Analyst
SMBC Nikko
Not Ranked
SMBC Nikko
¥1,700→¥2,000
Hold
-21.68%
Downside
Reiterated
02/16/26
SMBC Nikko Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
Morgan Stanley Analyst forecast on JP:4503
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
¥1,950→¥2,050
Hold
-19.72%
Downside
Reiterated
02/05/26
Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley
Daiwa Analyst forecast on JP:4503
Unknown Analyst
Daiwa
Not Ranked
Daiwa
¥1,600
Sell
-37.34%
Downside
Reiterated
01/29/26
Daiwa Sticks to Their Sell Rating for Astellas Pharma (ALPMF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on JP:4503
Miki Sogi
Bernstein
Bernstein
¥2,200
Hold
-13.84%
Downside
Reiterated
05/12/26
Astellas Rated Hold as Xtandi Headwinds Offset Pipeline Potential; Price Target Reiterated at ¥2,200
Citi Analyst forecast on JP:4503
Hidemaru Yamaguchi
Citi
Citi
¥2,500→¥2,400
Hold
-6.01%
Downside
Reiterated
05/01/26
Astellas Pharma (ALPMF) Gets a Hold from Citi
Goldman Sachs Analyst forecast on JP:4503
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
¥2,800→¥2,950
Buy
15.53%
Upside
Reiterated
04/28/26
Goldman Sachs Sticks to Its Buy Rating for Astellas Pharma (ALPMF)
UBS Analyst forecast on JP:4503
Unknown Analyst
UBS
Not Ranked
UBS
¥2,350→¥2,600
Hold
1.82%
Upside
Reiterated
04/16/26
Astellas Pharma (ALPMF) Receives a Hold from UBS
Jefferies Analyst forecast on JP:4503
Stephen Barker
Jefferies
Jefferies
¥2,800
Buy
9.65%
Upside
Reiterated
03/24/26
Jefferies Keeps Their Buy Rating on Astellas Pharma (ALPMF)
J.P. Morgan Analyst forecast on JP:4503
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
¥2,500
Hold
-2.10%
Downside
Reiterated
03/23/26
J.P. Morgan Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Mizuho Securities Analyst forecast on JP:4503
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
¥2,500
Hold
-2.10%
Downside
Reiterated
03/19/26
Astellas Pharma (ALPMF) Receives a Hold from Mizuho Securities
Macquarie Analyst forecast on JP:4503
Unknown Analyst
Macquarie
Not Ranked
Macquarie
¥2,500→¥2,800
Buy
9.65%
Upside
Reiterated
03/16/26
Macquarie Reaffirms Their Buy Rating on Astellas Pharma (ALPMF)
Nomura Analyst forecast on JP:4503
Unknown Analyst
Nomura
Not Ranked
Nomura
¥2,400→¥2,500
Hold
-2.10%
Downside
Downgraded
02/19/26
Nomura downgrades Astellas Pharma (ALPMF) to a Hold
SMBC Nikko Analyst forecast on JP:4503
Unknown Analyst
SMBC Nikko
Not Ranked
SMBC Nikko
¥1,700→¥2,000
Hold
-21.68%
Downside
Reiterated
02/16/26
SMBC Nikko Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
Morgan Stanley Analyst forecast on JP:4503
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
¥1,950→¥2,050
Hold
-19.72%
Downside
Reiterated
02/05/26
Astellas Pharma (ALPMF) Gets a Hold from Morgan Stanley
Daiwa Analyst forecast on JP:4503
Unknown Analyst
Daiwa
Not Ranked
Daiwa
¥1,600
Sell
-37.34%
Downside
Reiterated
01/29/26
Daiwa Sticks to Their Sell Rating for Astellas Pharma (ALPMF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astellas Pharma

3 Months
Stephen BarkerJefferies
Success Rate
1/2 ratings generated profit
50%
Average Return
+8.75%
Copying Stephen Barker's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +8.75% per trade.
1 Year
Stephen BarkerJefferies
Success Rate
1/2 ratings generated profit
50%
Average Return
+3.00%
Copying Stephen Barker's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +3.00% per trade.
2 Years
Stephen BarkerJefferies
Success Rate
1/2 ratings generated profit
50%
Average Return
+10.80%
Copying Stephen Barker's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +10.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4503 Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
3
4
4
5
4
Hold
5
9
11
9
6
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
9
14
16
14
10
In the current month, 4503 has received 4 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 4503 average Analyst price target in the past 3 months is 2,593.75.
Each month's total comprises the sum of three months' worth of ratings.

4503 Financial Forecast

4503 Earnings Forecast

Next quarter’s earnings estimate for 4503 is ¥46.61 with a range of ¥42.53 to ¥50.69. The previous quarter’s EPS was ¥24.29. 4503 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4503 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4503 is ¥46.61 with a range of ¥42.53 to ¥50.69. The previous quarter’s EPS was ¥24.29. 4503 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4503 has Performed in-line its overall industry.

4503 Sales Forecast

Next quarter’s sales forecast for 4503 is ¥558.44B with a range of ¥551.80B to ¥562.60B. The previous quarter’s sales results were ¥537.92B. 4503 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4503 has Performed in-line its overall industry.
Next quarter’s sales forecast for 4503 is ¥558.44B with a range of ¥551.80B to ¥562.60B. The previous quarter’s sales results were ¥537.92B. 4503 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4503 has Performed in-line its overall industry.

4503 Stock Forecast FAQ

What is JP:4503’s average 12-month price target, according to analysts?
Based on analyst ratings, Astellas Pharma Inc’s 12-month average price target is 2,593.75.
    What is JP:4503’s upside potential, based on the analysts’ average price target?
    Astellas Pharma Inc has 1.58% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Astellas Pharma Inc a Buy, Sell or Hold?
          Astellas Pharma Inc has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Astellas Pharma Inc’s share price target?
            The average share price target for Astellas Pharma Inc is 2,593.75. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ¥2,950.00 ,and the lowest forecast is ¥2,200.00. The average share price target represents 1.58% Increase from the current price of ¥2,553.5.
              What do analysts say about Astellas Pharma Inc?
              Astellas Pharma Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Astellas Pharma Inc?
                To buy shares of JP:4503, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.